FBRX - Forte Biosciences, Inc.
6.19
-0.130 -2.100%
Share volume: 12,299
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$6.32
-0.13
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-13-2024 | 08-14-2024 | 11-14-2024 | 03-28-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||
| Operating expenses | 7.804 M | 12.818 M | 8.629 M | 7.351 M | |
| Selling general and admin | 3.451 M | 7.078 M | 2.759 M | 2.121 M | |
| Research and development | 4.353 M | 5.740 M | 5.870 M | 5.230 M | |
| Total expenses | 7.804 M | 12.818 M | 8.629 M | 7.351 M | |
| 64.25% | -32.68% | -14.81% | |||
| Operating income | -7.804 M | -12.818 M | -8.629 M | -7.351 M | |
| Ebit | -7.420 M | -12.818 M | -8.392 M | -7.351 M | |
| Pretax income | -7.420 M | -12.818 M | -8.392 M | -6.848 M | |
| 72.75% | -34.53% | -18.40% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -7.420 M | -12.511 M | -8.392 M | -7.155 M | |
| -68.61% | 32.92% | 14.74% |
